I Kirman1, O H Nielsen. 1. Department of Medical Gastroenterology C, Herlev Hospital, University of Copenhagen, Denmark.
Abstract
OBJECTIVES: Interleukin-15 (IL-15) is a novel cytokine sharing many of the activities of IL-2. The goal of this study was to evaluate intracellular and serum IL-15 in ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Intracellular expression of IL-15 in peripheral blood mononuclear cells (PBMC) from UC patients, CD patients, and controls was studied using cell permeabilization and staining with monoclonal antibodies. Serum levels of IL-15 were detected using ELISA. RESULTS: Percentage of IL-15 expressing PBMC was increased in UC patients and in five of six of CD patients with moderate and severe disease activity compared with controls. The number of IL-15 expressing cells in patients with active inflammatory bowel disease (IBD) declined within 2 wk of treatment. Serum IL-15 reached detectable levels in 62.5% of UC patients with moderate and severe disease activity but not in UC patients with slight disease activity or in remission, neither in CD patients nor in controls. In vitro lipopolysaccharide (LPS)-induced activation of PBMC from controls was associated with up-regulation of intracellular IL-15 expression (p < 0.01) and release of IL-15. CONCLUSIONS: UC patients with moderate and severe disease activity have increased percentage of IL-15 expressing PBMC, which might be induced by in vivo cell activation and can lead to elevation of released IL-15 in serum. Increased IL-15 expression after in vitro LPS stimulation of control PBMC suggests a nonspecific production of this cytokine during the immunoinflammatory response.
OBJECTIVES:Interleukin-15 (IL-15) is a novel cytokine sharing many of the activities of IL-2. The goal of this study was to evaluate intracellular and serum IL-15 in ulcerative colitis (UC) and Crohn's disease (CD). METHODS: Intracellular expression of IL-15 in peripheral blood mononuclear cells (PBMC) from UC patients, CDpatients, and controls was studied using cell permeabilization and staining with monoclonal antibodies. Serum levels of IL-15 were detected using ELISA. RESULTS: Percentage of IL-15 expressing PBMC was increased in UC patients and in five of six of CDpatients with moderate and severe disease activity compared with controls. The number of IL-15 expressing cells in patients with active inflammatory bowel disease (IBD) declined within 2 wk of treatment. Serum IL-15 reached detectable levels in 62.5% of UC patients with moderate and severe disease activity but not in UC patients with slight disease activity or in remission, neither in CDpatients nor in controls. In vitro lipopolysaccharide (LPS)-induced activation of PBMC from controls was associated with up-regulation of intracellular IL-15 expression (p < 0.01) and release of IL-15. CONCLUSIONS: UC patients with moderate and severe disease activity have increased percentage of IL-15 expressing PBMC, which might be induced by in vivo cell activation and can lead to elevation of released IL-15 in serum. Increased IL-15 expression after in vitro LPS stimulation of control PBMC suggests a nonspecific production of this cytokine during the immunoinflammatory response.
Authors: P Matthys; H Dooms; P Rottiers; T Mitera; L Overgergh; G Leclercq; A Billiau; J Grooten Journal: Clin Exp Immunol Date: 2002-12 Impact factor: 4.330
Authors: Madeleine D Hu; Alexander D Ethridge; Rebecca Lipstein; Sushil Kumar; Yitang Wang; Bana Jabri; Jerrold R Turner; Karen L Edelblum Journal: J Immunol Date: 2018-06-08 Impact factor: 5.422
Authors: Y S Kim; W Maslinski; X X Zheng; A C Stevens; X C Li; G H Tesch; V R Kelley; T B Strom Journal: J Immunol Date: 1998-06-15 Impact factor: 5.422
Authors: Y Tagaya; G Kurys; T A Thies; J M Losi; N Azimi; J A Hanover; R N Bamford; T A Waldmann Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: Takashi Kawasaki; Mashkoor A Choudhry; Martin G Schwacha; Kirby I Bland; Irshad H Chaudry Journal: Am J Physiol Cell Physiol Date: 2008-11-05 Impact factor: 4.249